Skip to main content

Advertisement

SpringerLink
Log in

A Meta-Analysis of Nucleos(t)ide Analogues in Patients with Decompensated Cirrhosis Due to Hepatitis B

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The effect of nucleos(t)ide analogues therapy in patients with decompensated cirrhosis remains unclear.

Aim

The purpose of this study was to evaluate the effect of nucleos(t)ide analogues on decompensated cirrhotic patients.

Methods

An online search within PubMed, Web of Science, Embase, Cochrane Central of Register of Controlled Trials and China Biology Medicine disc from 1998-01-01 to 2011-09-05 was conducted. A meta-analysis was performed. Relative risks of mortality rate, Child-Pugh-Turcotte score and hepatitis B e-antigen (HBeAg) seroconversion of the decompensated patients were studied.

Results

Eight studies involving 511 patients were included. Data showed that lamivudine and telbivudine significantly decreased the mortality rate (relative risk 0.36, 95 % confidence interval 0.25–0.54), improved the Child-Pugh-Turcotte scores (mean difference −3.23, 95 % confidence interval −3.98 to −2.48) and promoted HBeAg seroconversion (relative risk 7.48, 95 % confidence interval 2.31–24.20).

Conclusion

For patients with decompensated cirrhosis, lamivudine and telbivudine significantly decrease the mortality rate and disease severity. Also, they promote their HBeAg seroconversion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242.

    Article  Google Scholar 

  2. Cárdenas A, dGinès P. Management of patients with cirrhosis awaiting liver transplantation. Gut. 2011;60:412–421.

    Article  PubMed  Google Scholar 

  3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.

    Article  PubMed  Google Scholar 

  4. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797–1803.

    Article  PubMed  Google Scholar 

  5. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–68.

    Article  PubMed  CAS  Google Scholar 

  6. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256–1263.

    Article  PubMed  CAS  Google Scholar 

  7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751.

    Article  PubMed  CAS  Google Scholar 

  8. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.

    Article  PubMed  CAS  Google Scholar 

  9. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348–356.

    Article  PubMed  CAS  Google Scholar 

  10. Zhang QQ, An X, Liu YH, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72.

    Article  PubMed  CAS  Google Scholar 

  11. Cochrane Library. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available at: http://www.cochrane-handbook.org/. Accessed 20.07.11.

  12. Cai ZF, Shang FM, Zhao WX, Lü F, Zhang Z. A clinical study on lamivudine treatment for decompensated cirrhosis due to hepatitis B. J Xi’an Jiaotong Univ (Med Sci). 2006;27:575–577.

    CAS  Google Scholar 

  13. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001;34:411–416.

    Article  PubMed  CAS  Google Scholar 

  14. Li CZ, Li TG, Gan XM Liu ZB. Clinical study on the treatment of 38 cases of decompensation liver cirrhosis by lamivudine. Chin J Infect Control. 2007;6:319–322.

    Google Scholar 

  15. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57–63.

    Article  PubMed  CAS  Google Scholar 

  16. Park TW, Park YM, Bae SH, et al. Efficacy and safety of long-term lamivudine therapy in the patients with decompensated liver cirrhosis secondary to hepatitis B. Taehan Kan Hakhoe Chi. 2002;8:428–435.

    PubMed  Google Scholar 

  17. Wang JF, Zhang WJ, Wu ZC, Wang MT. Clinical course of lamivudine in 56 patients with decompensated cirrhosis. Chin Rem Clin. 2006;6:547–548.

    Google Scholar 

  18. Wu HY, You DH. The efficacy of two-year’s telbivudine therapy on decompensated hepatitis B cirrhosis documentation. J Clin Hepatol. 2010;26:605–607.

    Google Scholar 

  19. Zhu GB. The efficacy of telbivudine therapy on decompensated hepatitis B cirrhosis documentation. Chin J Trauma Disabil Med. 2009;17:95–96.

    Google Scholar 

  20. Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003;9:49–56.

    Article  PubMed  Google Scholar 

  21. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433–439.

    Article  PubMed  Google Scholar 

  22. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–696.

    Article  PubMed  CAS  Google Scholar 

  23. Gane EJ, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011;31:676–684.

    Article  PubMed  CAS  Google Scholar 

  24. Kim YJ, Cho HC, Sinn DH, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 2012;27:306–312.

    Article  PubMed  CAS  Google Scholar 

  25. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719–727.

    Article  PubMed  Google Scholar 

  26. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the members of Prof. Xizhong Shen’s Laboratory for their helpful discussion and critical reading of the manuscript. The study was partly funded by the Major National Science and Technology Projects (2009ZX10004-301, 2008ZX10002-017), Shanghai Science and Technology Commission (10410709400, 10411950100), Shanghai Talent Development Foundation (2009-035), National Nature Science Foundation of China (30872503, 81000968, 81101540 and 81172273), The National Clinical Key Special Subject of China, Nature Science Foundation of Shanghai (12ZR1436000) and the Youth Innovation Promotion Association, Chinese Academy of Sciences.

Conflict of interest

The authors declare that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterology , Zhongshan Hospital of Fudan University, Shanghai, 200032, People’s Republic of China

    Yingnan Huang, Hao Wu, Shengdi Wu, Da Fu, Yushui Ma & Xizhong Shen

Authors
  1. Yingnan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengdi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Da Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yushui Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xizhong Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xizhong Shen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, Y., Wu, H., Wu, S. et al. A Meta-Analysis of Nucleos(t)ide Analogues in Patients with Decompensated Cirrhosis Due to Hepatitis B. Dig Dis Sci 58, 815–823 (2013). https://doi.org/10.1007/s10620-012-2414-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2414-y

Keywords

Search

Navigation